knowledge -WSS

knowledge

author：comprehensive 2025-08-12 06:42:59 - browse：818

Methadone and buprenorphine, both FDA-approved drugs, are considered the gold standard for treating opioid use disorder. They are so effective, in fact, that they are considered nearly curative for people who use them as prescribed. But a multitude of social and physical barriers to access mean that only about 20% of people who could benefit from these medicines have access to them. Access is even harder for pregnant people, who face additional stigmas and challenges.

Arthur Robin Williams, an addiction psychiatrist, and Judith Cole, a nurse practitioner, join the podcast this week to speak about the challenges during pregnancy, including the reality that federal law makes it possible for child protective services to be called when people receiving legal effective treatments for addiction give birth. Despite medications like methadone being fully safe during pregnancy, they continue to carry a stigma that can result in trauma for both birth parents and newborns.

“What’s getting conflated here is a result on a drug test, for instance, with actual abuse or neglect,” said Williams.

Williams and Cole wrote about this issue in their recent First Opinion essay, “Mothers in treatment for opioid use disorder shouldn’t also have to fight child protective services.” You can read more about barriers to addiction treatment in STAT reporter Lev Facher’s series “The War on Recovery.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts. And don’t forget to sign up for the First Opinion newsletter to read each week’s best First Opinion essays.

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Ed Silverman on new gene therapies, biosimilars, coffee, and more

focus

WSS

Mass General, Mayo Clinic look to monetize custom

Ed Silverman on new gene therapies, biosimilars, coffee, and more

To bolster infectious disease surveillance, genomics powerhouses team up

Head of FDA's diagnostics center, who led through Covid, retires

To bolster infectious disease surveillance, genomics powerhouses team up

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

hotspot

knowledge

leisure time

Heart attack and stroke risk calculators need revising

A solution to the after

Medicare details structure of new drug price negotiation program

Antivenom research: Lessons from HIV applied in search for universal antidote

Heart attack and stroke risk calculators need revising

In utero gene editing: an explainer

Psychedelics group wrestles with new pharma identity

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

entertainment

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Flu vaccine reformulation won't be easy, manufacturers warn

NIH study of ME/CFS points to clear biological hallmarks

Pumping milk in bathrooms at health conferences is common

Medicare bonuses could stop drug shortages under Senate plan

Microsoft launches AI tool for clinical documentation through Epic

Wikipedia

focus

Wikipedia

Wikipedia